As Co­di­ak en­ters 'next phase of growth,' Jen­nifer Whel­er steps in­to CMO role; Mark Tim­ney lines up his sec­ond CEO op­por­tu­ni­ty af­ter Pur­due Phar­ma reign

Most CMOs don’t start out as art stu­dents. But af­ter get­ting her bach­e­lor’s in art his­to­ry from Prince­ton Uni­ver­si­ty, Jen­nifer Whel­er de­cid­ed to go af­ter an MD from Cor­nell, kick­ing off a decades-long ca­reer in bio­phar­ma. Her next move? Lead­ing the team at Co­di­ak Bio­Sciences to de­liv­er ther­a­peu­tics us­ing a form of cel­lu­lar postal ser­vice called ex­o­somes.

“I was cap­ti­vat­ed by the sci­ence and the po­ten­tial for ex­o­somes to have trans­for­ma­tion­al im­pact in can­cer and oth­er dis­ease ar­eas,” the in­com­ing CMO told End­points News via email. “Co­di­ak has a po­tent com­bi­na­tion of great sci­ence and won­der­ful­ly ex­pe­ri­enced and kind peo­ple — it doesn’t get much bet­ter.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.